These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 3162176)

  • 21. Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men.
    Faure N; Labrie F; Lemay A; Bélanger A; Gourdeau Y; Laroche B; Robert G
    Fertil Steril; 1982 Mar; 37(3):416-24. PubMed ID: 6800852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
    Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
    J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A review of the Hammersmith Hospital, St. Bartholomew's Hospital, and Institute of Urology studies of buserelin in advanced prostatic cancer.
    Waxman J
    Am J Clin Oncol; 1988; 11 Suppl 1():S16-8. PubMed ID: 3133943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [1st clinical results of the treatment of locally advanced prostatic cancer with a powerful LH-RH analog: buserelin acetate].
    Nagel R; Borgmann V; Al-Abadi H; Schmidt-Gollwitzer M
    J Urol (Paris); 1983; 89(9):669-76. PubMed ID: 6425419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Management of true precocious puberty with a delayed-action Gn-RH analog].
    Julesz J; Iványi T; Domokos I; Janáky T; Faredin I; László F
    Orv Hetil; 1986 Dec; 127(49):3005-9. PubMed ID: 3099244
    [No Abstract]   [Full Text] [Related]  

  • 26. Induction and maintenance of castration by an LHRH analogue: D-Trp6 LHRH or decapeptyl.
    Fretin J; Demerle F; Jardin A
    Prog Clin Biol Res; 1987; 243A():245-7. PubMed ID: 2958855
    [No Abstract]   [Full Text] [Related]  

  • 27. [Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment].
    Oka H; Negoro H; Sugino Y; Iwamura H; Moroi S; Kawakita M
    Hinyokika Kiyo; 2003 Sep; 49(9):521-5. PubMed ID: 14598689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of prostatic cancer with intranasal administration of LHRH analog, Buserelin (Hoe 766) study of the optimum dosage of intranasal application].
    Niijima T; Kishimoto T; Shimazaki J; Yoshida O; Isurugi K
    Hinyokika Kiyo; 1988 Jul; 34(7):1309-19. PubMed ID: 3140622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.
    Spitz IM; Chertin B; Fridmans A; Farkas A; Belanger A; Hartman H; Labrie F
    Prostate Cancer Prostatic Dis; 2009; 12(1):100-3. PubMed ID: 18574491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Decapeptyl (D-Trp6-LH-RH) in the therapy of prostatic cancer with reference to the intramuscular administration of a depot preparation].
    Seppelt U; Bertermann H; Saerbeck C
    Urologe A; 1986 Sep; 25(5):298-301. PubMed ID: 2947371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gn-RH antagonist possible response, after Gn-RH agonist failure in a man with metastatic prostate cancer.
    Rocco B; Ferrari M; Scardino E; Matei DV; Verweij F; Varela R; De Cobelli O
    Anticancer Res; 2005; 25(1B):577-8. PubMed ID: 15816630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pretreatment with chlormadinone acetate in prostate cancer patients treated with a luteinizing hormone-releasing hormone analogue].
    Yamamoto A; Sumiyoshi Y; Miyake N; Yokozeki H; Kanayama H; Kagawa S
    Hinyokika Kiyo; 1998 Aug; 44(8):557-63. PubMed ID: 9783191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparative study of a long acting luteinizing hormone releasing hormone agonist (Decapeptyl) and orchiectomy in the treatment of advanced prostatic cancer. Preliminary report.
    De Sy WA; de Meyer JM; Casselman J; De Smet R; Renders G; Schelfhout W; De Wilde P
    Acta Urol Belg; 1986; 54(2):221-9. PubMed ID: 2942015
    [No Abstract]   [Full Text] [Related]  

  • 34. Suppression of testicular steroidogenesis by the GnRH agonistic analogue Buserelin (HOE-766) in patients with prostatic cancer: studies in relation to dose and route of administration.
    Tolis G; Faure N; Koutsilieris M; Lemay A; Klioze S; Yakabow A; Fazekas AT
    J Steroid Biochem; 1983 Jul; 19(1C):995-8. PubMed ID: 6411994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.
    Tolis G; Ackman D; Stellos A; Mehta A; Labrie F; Fazekas AT; Comaru-Schally AM; Schally AV
    Proc Natl Acad Sci U S A; 1982 Mar; 79(5):1658-62. PubMed ID: 6461861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Zoladex in prostatic carcinoma].
    Di Silverio F; Serio M
    Drugs Exp Clin Res; 1990; 16 Suppl():19-29. PubMed ID: 2150501
    [No Abstract]   [Full Text] [Related]  

  • 38. Reversibility of androgen deprivation therapy in patients with prostate cancer.
    Fridmans A; Chertin B; Koulikov D; Lindenberg T; Gelber H; Leiter C; Farkas A; Spitz IM
    J Urol; 2005 Mar; 173(3):784-9. PubMed ID: 15711270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of the initial testosterone surge induced by a luteinizing hormone-releasing hormone analogue in prostate cancer patients: the endocrinological effects of pretreatment with chlormadinone acetate.
    Yamamoto A; Sumiyoshi Y; Miyake N; Yokozeki H; Kanayama H; Kagawa S
    J Med Invest; 1999 Feb; 46(1-2):55-8. PubMed ID: 10408158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of gonadotropin-releasing hormone analogue in advanced prostatic cancer: 3 years clinical experience.
    Matzkin H; Greenstein A; Kaver I; Braf Z
    Isr J Med Sci; 1989 Jul; 25(7):388-92. PubMed ID: 2474522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.